Literature DB >> 7571829

Selective risk group strategies in Europe.

W Jilg1.   

Abstract

Most countries in northern and western Europe belong to areas with a low endemicity of hepatitis B virus (HBV). When HBV vaccines became available, these countries adopted a vaccination strategy that targeted groups at high risk of hepatitis B. However, it became obvious that this strategy, despite giving good protection to those who had been vaccinated, had largely failed. This was firstly because, with few exceptions (e.g. haemodialysis patients and haemophiliacs), only medical and dental workers were vaccinated in any great numbers, whereas only a few individuals in other risk groups were reached. Second, it was found that less than half of all hepatitis B cases occurred in individuals in typical high-risk groups. In Germany, for example, about three-quarters of all infections occur in people who would never be reached by the high-risk vaccination strategy, most of these individuals having been infected by heterosexual contact. Thus a universal vaccination strategy has to be implemented to control the spread of hepatitis B in the population and to eventually eliminate the disease.

Entities:  

Mesh:

Year:  1995        PMID: 7571829     DOI: 10.1016/0264-410x(95)80049-j

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Targeted hepatitis B vaccination--a cost effective immunisation strategy for the UK?

Authors:  J R Williams; D J Nokes; R M Anderson
Journal:  J Epidemiol Community Health       Date:  1996-12       Impact factor: 3.710

2.  Decline of hepatitis B infection in Greece.

Authors:  M Stamouli; V Gizaris; G Totos; G Papaevangelou
Journal:  Eur J Epidemiol       Date:  1999-05       Impact factor: 8.082

3.  [Hepatitis B virus infection and vaccine-induced immunity: the role of sociodemographic determinants : Results of the study "German Health Interview and Examination Survey for Adults" (DEGS1, 2008-2011)].

Authors:  Annika Brodzinski; Angela Neumeyer-Gromen; Sandra Dudareva; Ruth Zimmermann; Ute Latza; Viviane Bremer; Christina Poethko-Müller
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2021-12-27       Impact factor: 1.513

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.